Evidence map›Paper›PMID 40871042›Full record

ArticlePharmaceutics2025

Drug Repurposing for Kala-Azar.

Biljana Arsić, Budimir S Ilić, Andreas Maier, Michael Hartung, Jovana Janjić, Jelena Milićević, Jan Baumbach

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Tropical medicine and infectious disease · 2026
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Biljana ArsićDepartment of Chemistry, Faculty of Sciences and Mathematics, University of Niš, Višegradska 33, 18000 Niš, Serbia.ORCID 0000-0002-1248-5864
Budimir S IlićDepartment of Chemistry, Faculty of Medicine, University of Niš, Blvd. Dr Zorana Đinđića 81, 18000 Niš, Serbia.ORCID 0000-0002-2808-3501
Andreas MaierInstitute for Computational Systems Biology, University of Hamburg, Albert-Einstein-Ring 8-10, 22607 Hamburg, Germany.ORCID 0000-0003-4408-0068
Michael HartungInstitute for Computational Systems Biology, University of Hamburg, Albert-Einstein-Ring 8-10, 22607 Hamburg, Germany.ORCID 0000-0002-3992-0125
Jovana JanjićFaculty of Biology, University of Belgrade, Studentski trg 16, 11000 Belgrade, Serbia.
Jelena MilićevićLaboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences "Vinča", University of Belgrade, Mike Petrovića Alasa 12-14, 11000 Belgrade, Serbia.ORCID 0000-0001-7783-6218
Jan BaumbachInstitute for Computational Systems Biology, University of Hamburg, Albert-Einstein-Ring 8-10, 22607 Hamburg, Germany.

Funding

European Union or the European Research Executive Agency N/AMinistry of Science, Technological Development and Innovation of the Republic of Serbia projects Nos. 451-03-47/2023-01/200124, 451-03-66/2024-03/200124, 451-03-136/2025-03/200124 (Biljana Arsić), 451-03-137/2025-03/200113 (Budimir S. Ilić), 451-03-47/2023-01/200017, 451-03-66/2024-03/200017 and 451-03-136/2025-03/200017 (Jelena Milićević)Royal Society of Chemistry C23-3732208591Swiss State Secretariat for Education, Research, and Innovation (SERI) 22.00115
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

drug repurposingentecavirmolecular dockingmolecular dynamics simulationnifuroxazidePTR1Rab5aSTAT3 pathwayvalganciclovirvisceral leishmaniasis

Identifiers

PMID40871042
PMCPMC12388976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.